Approximately 20% of advanced gastric or gastroesophageal junction adenocarcinomas have human epidermal growth factor receptor 2 (ERBB2, or HER2) amplification or overexpression [6]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.